Targeting ‘hidden pocket’ for treatment of stroke and seizure

The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists at Cold Spring Harbor Laboratory have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.

According to Professor Hiro Furukawa, the senior scientist who oversaw this work, “it really comes down to chemistry.”

When the human brain is injured, such as during a stroke, parts of the brain begin to acidify. This acidification leads to the rampant release of glutamate.

“We suddenly get more glutamate all over the place that hits the NMDA receptor and that causes the NMDA receptor to start firing quite a lot,” explains Furukawa.

Full story at Science Daily

Underlying cause of brain injury in stroke

New research shows how the novel drug QNZ-46 can help to lessen the effects of excess release of glutamate in the brain — the main cause of brain injury in stroke.

Published inĀ Nature Communications, the study shows how identifying the source of damaging glutamate in stroke leads to discovery of brain protection with QNZ-46, a novel form of preventative treatment with clinical potential.

Existing studies show that restricted blood supply promotes the excess release of glutamate. The glutamate binds to receptors, over-stimulating them and leading to the break-down of myelin — the protective sheath around the nerve fibre (axon).

Full story at Science Daily